-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246

Benzinga·10/12/2026 11:31:35
Listen to the news
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and lowers the price target from $270 to $246.